Division of Critical Care, Department of Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at IU Health, Indianapolis, Indiana.
Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Los Angeles and University of Southern California, Los Angeles, California.
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1389-1397. doi: 10.1164/rccm.201909-1807OC.
Few data exist to guide early adjunctive therapy use in pediatric acute respiratory distress syndrome (PARDS). To describe contemporary use of adjunctive therapies for early PARDS as a framework for future investigations. This was a preplanned substudy of a prospective, international, cross-sectional observational study of children with PARDS from 100 centers over 10 study weeks. We investigated six adjunctive therapies for PARDS: continuous neuromuscular blockade, corticosteroids, inhaled nitric oxide (iNO), prone positioning, high-frequency oscillatory ventilation (HFOV), and extracorporeal membrane oxygenation. Almost half (45%) of children with PARDS received at least one therapy. Variability was noted in the median starting oxygenation index of each therapy; corticosteroids started at the lowest oxygenation index (13.0; interquartile range, 7.6-22.0) and HFOV at the highest (25.7; interquartile range, 16.7-37.3). Continuous neuromuscular blockade was the most common, used in 31%, followed by iNO (13%), corticosteroids (10%), prone positioning (10%), HFOV (9%), and extracorporeal membrane oxygenation (3%). Steroids, iNO, and HFOV were associated with comorbidities. Prone positioning and HFOV were more common in middle-income countries and less frequently used in North America. The use of multiple ancillary therapies increased over the first 3 days of PARDS, but there was not an easily identifiable pattern of combination or order of use. The contemporary description of prevalence, combinations of therapies, and oxygenation threshold for which the therapies are applied is important for design of future studies. Region of the world, income, and comorbidities influence adjunctive therapy use and are important variables to include in PARDS investigations.
关于小儿急性呼吸窘迫综合征(PARDS)早期辅助治疗的应用,目前仅有少量数据可供指导。为了描述 PARDS 早期辅助治疗的当代应用,为未来的研究提供框架。这是一项前瞻性、国际性、跨时相观察性研究的预先计划子研究,该研究在 10 个研究周内纳入了 100 个中心的 PARDS 患儿。我们调查了 PARDS 的 6 种辅助治疗方法:持续神经肌肉阻滞、皮质类固醇、吸入一氧化氮(iNO)、俯卧位、高频振荡通气(HFOV)和体外膜氧合。近一半(45%)的 PARDS 患儿接受了至少一种治疗。每种治疗的起始氧合指数中位数存在差异;皮质类固醇的起始氧合指数最低(13.0;四分位距,7.6-22.0),HFOV 最高(25.7;四分位距,16.7-37.3)。连续神经肌肉阻滞最常用,占 31%,其次是 iNO(13%)、皮质类固醇(10%)、俯卧位(10%)、HFOV(9%)和体外膜氧合(3%)。皮质类固醇、iNO 和 HFOV 与合并症相关。俯卧位和 HFOV 在中等收入国家更常见,在北美使用较少。PARDS 发病后前 3 天,辅助治疗的应用频率增加,但组合或使用顺序没有明显模式。辅助治疗的应用流行率、治疗组合和氧合阈值的当代描述对未来研究的设计很重要。世界区域、收入和合并症影响辅助治疗的应用,是 PARDS 研究中重要的变量。